PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9109854-0	1997	Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.	Metformin	0-9	lipoprotein(a)	Homo sapiens	93-107	
16882108-19	2006	However, long-term treatment with metformin plus pioglitazone significantly reduced Lp(a) plasma levels, whereas metformin + rosiglitazone did not.	Metformin	34-43	lipoprotein(a)	Homo sapiens	84-89	
16882108-20	2006	CONCLUSION: For patients with type 2 diabetes mellitus and metabolic syndrome, combined treatment with metformin and rosiglitazone or pioglitazone is safe and effective, However, the pioglitazone combination also reduced the plasma Lp(a) levels whereas the rosiglitazone combination did not.	Metformin	103-112	lipoprotein(a)	Homo sapiens	232-237	
9109854-6	1997	Metformin decreases Izero in hyperinsulinemic PCOS patients, reverses the hyperinsulinemia-driven endocrinopathy, decreases PAI-1, and decreases Lp(a), and should thus reduce the increased risk of atherothrombosis in PCOS.	Metformin	0-9	lipoprotein(a)	Homo sapiens	145-150